PART II — THE MECHANISM
CJC-1295 Research: The GHRH Receptor, the Albumin Linker, and the Pulsatile Signal
CJC-1295 binds a class-B G-protein-coupled receptor on pituitary somatotrophs, amplifies the body's own pulsatile growth hormone release, and — in its DAC variant — keeps the signal running for days. The molecular detail and the published results.
CJC-1295 Mechanism of Action
CJC-1295 binds the growth hormone-releasing hormone receptor — GHRHR, encoded on chromosome 7p14.3 — a class B G-protein-coupled receptor on pituitary somatotrophs [20]. Agonist binding activates the Gαs subunit, raises intracellular cAMP through adenylyl cyclase, activates protein kinase A, phosphorylates CREB, induces the somatotroph-specific transcription factor Pit-1, and triggers voltage-gated Ca2+ influx that drives exocytosis of preformed GH secretory granules [05]. The receptor's cryo-EM structure was published in 2020 [05]; a 2025 review of GHRHR signaling frames it as the single shared molecular target across every clinically studied GHRH analog — sermorelin, tesamorelin, CJC-1295, modified GRF 1-29 [20].
The pulse architecture matters. Endogenous GH is released in discrete bursts, chiefly during slow-wave sleep, not continuously. GHRH analogs amplify the amplitude of those bursts; exogenous recombinant GH overrides the rhythm with sustained apulsatile elevation [01]. This is the mechanistic argument for studying GHRH analogs at all: they work with the body's clock rather than overriding it.
GHRH receptor agonism and pulsatile GH amplification
CJC-1295 binds pituitary GHRHR and amplifies endogenous pulsatile GH release from somatotrophs rather than supplying exogenous GH itself. The DAC variant extends this amplification across days; the non-DAC variant produces a single GH pulse lasting roughly 60-90 minutes versus 15-20 minutes for native sermorelin [13].
CJC-1295 DAC vs CJC-1295 (Modified GRF 1-29)
CJC-1295 DAC and the variant sold as CJC-1295 no DAC are two distinct peptides with the same 29-residue backbone. The difference is one linker.
The DAC linker is a maleimidopropionyl group attached to a 30th C-terminal lysine. In plasma, the maleimide reacts selectively with the free thiol of Cys34 on human serum albumin to form a stable covalent thioether [02][12]. The conjugated peptide rides circulating albumin, whose half-life is near 19 days, and is shielded from renal and proteolytic clearance. In Teichman's healthy-adult trials, plasma CJC-1295 was estimated at a 5.8- to 8.1-day half-life and produced pharmacologically relevant GH and IGF-1 elevation for six to eleven days from a single subcutaneous injection [01].
In ConjuChem's preclinical rat assay, albumin-bound CJC-1295 immunoreactivity appeared in circulation within 15 minutes of injection and persisted beyond 72 hours [03][14]. The same paper identified CJC-1295 as the most potent of three maleimido hGRF(1-29) bioconjugates synthesized, producing a four-fold increase in GH area-under-curve over two hours compared with unmodified hGRF(1-29) in cultured rat anterior pituitary cells [03].
CJC-1295 without DAC (Modified GRF 1-29)
CJC-1295 no DAC is the same peptide minus the albumin linker. Its half-life in plasma is approximately 30 minutes — extended from native sermorelin's sub-10-minute half-life by the DPP-IV-resistant substitutions, but no longer than that [04][13]. Research protocols administer it as multiple daily subcutaneous injections, typically 100-500 mcg per injection, one to three times daily [13]. The GH pulse it generates is roughly 60-90 minutes long, a more physiologic 'pulse-like' release pattern than the multi-day signal the DAC variant produces.
Modified GRF 1-29 (Tetra-Substituted GHRH 1-29)
Modified GRF 1-29 is the scientific name for tetrasubstituted GHRH(1-29) — the same peptide as CJC-1295 no DAC, with the same four substitutions (D-Ala2, Gln8, Ala15, Leu27) [02]. The 'modified GRF' nomenclature is the one used in mechanistic and pharmacokinetic literature; 'CJC-1295 no DAC' is the lay-and-research-chemical label. Treating the two terms as synonyms is correct; treating modified GRF 1-29 as equivalent to the DAC variant is not.
Researched Effects of CJC-1295
Two pharmacodynamic endpoints anchor the literature. First, growth hormone: single ascending subcutaneous doses up to 250 mcg/kg in healthy adults produced two- to ten-fold elevations in mean plasma GH sustained for six days or more [01]. Second, IGF-1: those same doses raised mean serum IGF-1 1.5- to 3-fold for nine to eleven days [01]. Multiple-dose Phase 1 trials, with weekly or biweekly subcutaneous administration, maintained mean IGF-1 above baseline for up to 28 days [01].
In the cultured rat anterior pituitary assay, CJC-1295 produced a four-fold increase in GH area-under-curve over two hours compared to unmodified hGRF(1-29) [03]. Pulsatile release was preserved — the analog amplified existing pulse amplitude rather than collapsing the pulse architecture into continuous elevation [01].
No published Phase 2 efficacy data has appeared in peer-reviewed form. ConjuChem registered NCT00267527 for HIV-associated visceral obesity, enrolling roughly 192 adults on weekly escalating doses of 60-240 mcg/kg [18]. The program was halted before completion, and the efficacy endpoints — body composition, visceral fat reduction, IGF-1 area-under-curve — were never published.
CJC-1295 Results in Published Trials
Two peer-reviewed primary papers carry most of the load. Jetté 2005 in Endocrinology is the preclinical pharmacology paper: receptor binding, in vitro pituitary cell secretion, in vivo rat plasma persistence, and identification of CJC-1295 as the most potent of three maleimido bioconjugates [03]. Teichman 2006 in JCEM is the human Phase 1 paper: two ascending-dose trials in healthy adults, the 5.8- to 8.1-day half-life, the two- to ten-fold GH elevation, the 1.5- to 3-fold IGF-1 elevation, the 28-day multi-dose IGF-1 trajectory [01].
Analytical literature has continued. Henninge 2010 confirmed CJC-1295's identity in a seized pharmaceutical preparation by LC-HRMS/MS, establishing reference data for anti-doping detection [08]. Timms 2019 developed an immunoaffinity-capture LC-MS/MS confirmation for albumin-bound CJC-1295 in equine plasma [09]. A 2021 review surveyed antibody-free nano-LC-HRMS/MS methods capable of detecting GHRH synthetic analogs at sub-picogram-per-milliliter sensitivity in urine [19]. The compound is a Prohibited Substance under Section S2 of the World Anti-Doping Agency Code and is detected by validated assays in WADA-accredited laboratories [15].
Time course of reported effects in published studies
Pulsatile GH amplitude rose within 24 to 48 hours of a single subcutaneous dose in healthy adults and remained elevated for six to nine days; serum IGF-1 rose more slowly and stayed elevated for nine to eleven [01]. In the 28- to 49-day multi-dose Phase 1 trials, weekly or biweekly subcutaneous administration of 30-60 mcg/kg maintained mean IGF-1 above baseline across the full trial window [01]. No published trial has reported a body-composition endpoint in the public literature.
CJC-1295 vs Ipamorelin: Class and Mechanism
CJC-1295 is a GHRH analog. Ipamorelin is a growth hormone secretagogue receptor agonist — it binds GHS-R1a, the ghrelin receptor, not the GHRH receptor [10]. The two molecules act on two different receptors that signal through two different intracellular cascades and converge on the same target cell. GHRHR signals through Gαs / cAMP / PKA; GHS-R1a signals through Gq / PLC / IP3 / Ca2+ [05][10]. Co-administration of a GHRH receptor agonist with a GHS-R agonist produced GH responses substantially greater than either alone in the Bowers laboratory's clinical pharmacodynamic studies, because the two pathways converge synergistically on somatotroph GH exocytosis rather than competing [10].
This is a mechanistic observation about receptor pharmacology in the published record. It is not an endorsement of any stacking protocol. The portfolio is editorial.
Endpoints in published trials
Across the Teichman 2006 record the measured endpoints were: pulsatile GH amplitude and area-under-curve, mean serum GH across the dosing interval, serum IGF-1, serum IGFBP-3, the pharmacokinetic parameters of the peptide itself (peak plasma concentration, time to peak, half-life), and adverse-event tracking [01]. The Phase 2 HIV lipodystrophy program (NCT00267527) added visceral adipose tissue by imaging as the primary efficacy endpoint, but that data was never published [18].
Research applications studied to date
CJC-1295 has been studied as a long-acting GH secretagogue in healthy adults (Teichman 2006 Phase 1) and in HIV-associated visceral obesity (the discontinued Phase 2 NCT00267527) [01][18]. Preclinical work has examined GHRH receptor binding, pituitary cell secretion, rat plasma pharmacokinetics, and the albumin-bioconjugation kinetics that underwrite the weekly-dosing model [03][14]. The compound has also been studied in animal models of muscle, bone, and fat metabolism as a tool for amplifying the GH/IGF-1 axis in research contexts. No published study has demonstrated meaningful change in serum testosterone — CJC-1295 acts on the GHRH/GH/IGF-1 axis, not the hypothalamic-pituitary-gonadal axis [01].